![GSK plc Website](https://cdn.finchat.io/275442.png)
GSK plc
LSE-GSK
Company Overview
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Name
GSK plc
CEO
Ms. Emma Natasha Walmsley
Website
www.gsk.com
Sector
Pharmaceuticals
Year Founded
1715
Profile
Market Cap
£67.36B
EV
£80.72B
Shares Out
4,078.96M
Revenue
£31.45B
Employees
70,212
Margins
Gross
72.78%
EBITDA
34.93%
Operating
28.58%
Pre-Tax
15.96%
Net
12.83%
FCF
19.54%
Returns (5Yr Avg)
ROA
9.71%
ROTA
-58.61%
ROE
45.64%
ROCE
15.77%
ROIC
11.14%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
£19.68
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
£2,983M
Net Debt
£13.96B
Debt/Equity
1.23
EBIT/Interest
13.55
Growth (CAGR)
Rev 3Yr
3.48%
Rev 5Yr
-0.2%
Rev 10Yr
2.49%
Dil EPS 3Yr
-3.45%
Dil EPS 5Yr
-2.51%
Dil EPS 10Yr
-2.12%
Rev Fwd 2Yr
4.92%
EBITDA Fwd 2Yr
0.21%
EPS Fwd 2Yr
6.56%
EPS LT Growth Est
8.4%
Dividends
Yield
—
Payout
60.48%
DPS
£0.6
DPS Growth 3Yr
-15.66%
DPS Growth 5Yr
-9.71%
DPS Growth 10Yr
-4.98%
DPS Growth Fwd 2Yr
4.99%